BioCentury
ARTICLE | Clinical News

AVB-620: Phase I started

November 16, 2015 8:00 AM UTC

Avelas began an open-label, dose-escalation, U.S. Phase I trial to evaluate single doses of IV AVB-620 in up to 39 patients with stage I-III breast cancer prior to surgery. ...